Skip to main navigation Skip to search Skip to main content

Biomarker assessment and pharmacology of HP518, an AR PROTAC degrader from the phase 1 dose-escalation study in patients with metastatic castration-resistant prostate cancer (mCRPC)

  • Arun Azad
  • , Craig R. Underhill
  • , Howard Gurney
  • , Lisa Horvath
  • , Mark Voskoboynik
  • , Scott Ellerington
  • , Yiyun Dai
  • , Ivan King
  • , Frank Perabo
  • , George Guo

Research output: Contribution to journal › Meeting abstract › peer-review

Fingerprint

Dive into the research topics of 'Biomarker assessment and pharmacology of HP518, an AR PROTAC degrader from the phase 1 dose-escalation study in patients with metastatic castration-resistant prostate cancer (mCRPC)'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science